Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein

Arthur E. Frankel, Miloslav Beran, Donna E. Hogge, Bayard L. Powell, Andrew Thorburn, Yong Q. Chen, Daniel A. Vallera

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Objective. In previous studies, we demonstrated that the diphtheria toxin-urokinase fusion protein DTAT was selectively toxic to acute myeloid leukemia (AML) cell lines overexpressing the CD87 urokinase receptor. In the present study, we analyzed the sensitivity of patient leukemic progenitors to DTAT and correlated the sensitivity with CD87 expression. Materials and Methods. We isolated leukemic blasts by density gradient centrifugation and performed immunophenotyping by flow cytometry and blast sensitivity measurements by inhibition of cell proliferation and colony formation in semisolid media. Results. We found CD87 overexpression in 18 (25%) of 71 patient leukemic blast samples, including 18 (28%) of 64 myeloid malignancies and 0 (0%) of 7 lymphoid malignancies. DTAT was toxic to patient leukemic blasts by both proliferation inhibition (IC50 ≤1 nM DTAT in 18/69 evaluable samples) and colony formation inhibition (>85% inhibition by 10 nM DTAT in 11/41 evaluable samples). Only AML and chronic myeloid leukemia (CML) blast crisis blasts (18/61 [30%]) were sensitive to DTAT by the proliferation inhibition assay. Lymphoid leukemia and chronic phase CML/chronic myelomonocytic leukemia (CMML) progenitors were insensitive to DTAT by the proliferation inhibition assay (n = 7 and n = 3, respectively). Similarly, normal marrow progenitors were insensitive to DTAT by both proliferation inhibition (n = 2) and colony inhibition (n = 5) assays. The DTAT toxicity measured by both proliferation inhibition assay and colony inhibition assay correlated with CD87 density (p < 0.0001 and p = 0.001, respectively). DTAT toxicity results were similar for leukemic blasts measured by either of the two assays (p = 0.0002). Conclusions. This study provides the first evidence that a urokinase receptor targeted diphtheria fusion protein is toxic to patient AML blasts. The work also suggests that blast proliferation assays yield similar responses to leukemia colony-forming cell colony assays.

Original languageEnglish (US)
Pages (from-to)1316-1323
Number of pages8
JournalExperimental Hematology
Issue number11
StatePublished - Nov 1 2002

Bibliographical note

Funding Information:
This work was supported by grants from the National Institutes of Health (R21CA90550, R01CA076178, and R01CA090263); the Leukemia and Lymphoma Society (LSA#6114); and support from Wake Forest University. The authors thank Poqui Gu, Jason Ramage, and Gitte Gerhard for excellent technical assistance and the patients and physicians of affiliated hospitals for donating blood samples.


Dive into the research topics of 'Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein'. Together they form a unique fingerprint.

Cite this